The safety and effectiveness of binaural adeno-associated virus 1 (AAV1)-human otoferlin (hOTOF) therapy in five children with autosomal recessive deafness 9 (DFNB9).
Kronos Bio swivels focus to multiple melanoma
Share this article Cancer patient in hospital bed. Kronos Bio is discontinuing the development of its AML therapy laanraplenib. Credit: E+ via Getty Images Kronos